The Canadian Lipid lowering drug market size stood at around USD xx billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

The market size of Canadian lipid-lowering drugs will continue to expand, and the growth rate will gradually increase. The growth of the cholesterol lowering drugs market can be attributed to the rise in the prevalence of cardiovascular diseases such as coronary artery disease in Canada. High cholesterol is one of the major risk factors for coronary heart disease and stroke, and despite available treatment, including statins, many Canadian patients face an ongoing challenge of achieving their target low-density lipoprotein cholesterol (LDL-C) levels. In fact,approximately 40% of Canadians live with high cholesteroland45% of them do not meet their target LDL-C levels



Market Drivers

The growing prevalence of different cardiovascular diseases, which are caused by various factors such as increased obesity, changing food habits, higher alcohol consumption, and smoking is driving the cholesterol lowering drugs market. Growing awareness about bad cholesterol is one of the key drivers that is triggering the growth of the cholesterol lowering drugs market. Companies are referring to investigational studies to understand which drugs are well-tolerated inpatients and make improvements according to the results. Moreover, the development of drug formulation for cholesterol lowering, new therapies such as the emergence of PCSK9 inhibitors, and growing awareness about cardiovascular diseases are some of the major factors responsible for the growth of the cholesterol lowering drugs market. Lucrative opportunities in emerging economies are expected to provide significant prospects for the manufacturers in the industry.